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lines for an early switch from intravenous to oral antibiotic therapy
were introduced. The pharmacist checked all medical charts on daily
rounds. Interventions took place by giving advice in individual cases.
Results of a three-month intervention period are discussed.
Results: During the baseline period, the antibiotic therapy of 77 sur-
gical and 32 internal medicine patients was reviewed. On average,
the pharmacist re-evaluated the choice of antibiotics three times
during the course of treatment. On the surgical wards optimal treat-
ment was achieved in 42% of scored therapies. The most frequent
deviations were 1) choice of antibiotics (28%) and 2) route of admin-
istration (14%). On the internal medicine ward 51% of reviewed
therapies met all criteria. The deviations on this ward were evenly
spread. In the intervention period, 64% of scored therapies in the sur-
gical versus 77% in the internal medicine wards were classified as
optimal. All evaluated parameters improved. In both departments,
deviations from the formulary were mainly caused by reluctance to
use intravenous gentamicin. This could not be altered by the afore-
mentioned interventions and influenced the outcome.
Conclusion: This study clearly shows that distributing an antibiotic
formulary is not sufficient to optimise antibiotic treatment. Much
effort is required to implement an antibiotic formulary to it’s full
extent. We have shown that significant improvement can be achieved
by above-mentioned interventions. By organising consensus meet-
ings we expect to eliminate some systematic deviations, and thus
improving the results even more.
Improving the quality of antibiotic treatment in 
a Dutch hospital
I. H. Bartelink1, R. J. M. Brüggemann1, 
G. J. van Asselt2, J. W. P. M. Overdiek1, 
P. A. M. M. Boermans1 & P. M. Oostvogel2
1Central Hospital Pharmacy The Hague, 2Department of
Medical Microbiology, Medical Centre Haaglanden, The Hague,
The Netherlands
Introduction: Although antibiotic formularies have been established
in many Dutch hospitals, the implementation of their guidelines has
not been studied extensively. The goal of our study was to optimise
the use of the antibiotic formulary in Medical Centre Haaglanden, a
777-beds hospital on two locations. This study focuses on one of
these locations.
Methods: To assess quality of baseline antibiotic therapy, a pharma-
cist specifically assigned for this study, performed a two-month eval-
uation on internal medicine and surgical wards. Guidelines of the
antibiotic formulary were considered as the golden standard. Crite-
ria to judge the quality of therapy were correctness of: 1) dose, 2)
route of administration, 3) length of therapy, 4) choice of antibiotics
and 5) justification of the use of antibiotics. A treatment was defined
as optimal when all these criteria were met. During the course of
therapy the treatment was reevaluated continuously.
After assessment of the baseline, the following interventions were
performed. Physicians and nurses were instructed monthly. Guide-
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hiv-1-infected children
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Introduction: The protease inhibitor (PI) nelfinavir (NFV) has been
shown to produce a durable antiretroviral response when used in
combination therapy in HIV-1 infected adults and children. NFV is
available as a powder and a tablet formulation. The recommended
dosage for patients aged 2 to 13 years is 20 to 30 mg/kg tid. Phar-
macokinetics (PK) of PIs (including NFV) show high interpatient
variability, especially in children. Suboptimal exposure to NFV has
been correlated with virologic failure. Knowledge of the population
PK of NFV in pediatric patients may be used to optimise therapy. In
order to establish the PK of NFV and factors involved in the vari-
ability of therapy, a population PK analysis was performed in a
cohort of HIV-1-infected children.
Methods: Patients (aged 0.1–18.7 yrs, weight 4–65 kg) were
recruited from the Emma Children’s Hospital, Amsterdam, the
Netherlands. All participated in an ongoing open-label observational
study to evaluate the efficacy and safety of triple therapy with NFV,
stavudine (d4T) and lamivudine (3TC) in PI-naïve HIV-1-infected
children. NFV was administered as tablets (250 mg) or as powder
(50 mg/g powder) in a dose of 30 mg/kg tid or 45mg/kg bid. Popu-
lation PK parameters (clearance (CL/F), volume of distribution
(V/F) and absorption rate constant (Ka)) were established after log
transformation of the data. Interindividual (IIV) and interoccasion
variability (IOV) in the PK parameters were estimated. Residual
variability was modelled with an exponential model. A number of
covariates of interest were tested for inclusion in the population 
PK model by stepwise addition into the basis model. A decrease of
3.8 in the objective function (goodness of fit characteristic) was
deemed significant (p < 0.05). NONMEM (Version V1.1) was used
throughout.
Results: A total of 694 plasma concentrations were available, con-
sisting of full PK curves at either tid or bid dosing (27 curves from
Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 11 April 2003
356 57:3 Br J Clin Pharmacol
19 children), and of plasma concentrations at single time points. A
one-compartment model with fist order absorption and elimination
process and a lagtime (Tlag) best described the data. CL/F and V/F
were allometrically scaled for median bodyweight (18 kg). CL/F for
NFV was 33.7 L/h with an IIV and IOV of 29% and 34%, respec-
tively. V/F for NFV was 193 L, Ka was 0.65 h-1 (IIV 52%) and Tlag
was 0.33 h. Two covariates were found to improve the fit when added
to the basic model. CL/F of NFV was correlated with age. CL/F
decreased with increasing age (e.g., CL/F at age 2 is 35.9 L/h, at age
12 is 28.7 L/h (p < 0.05)). The NFV formulation was correlated with
the bioavailability (F). F was increased with 43% (±15%) in patients
who received the powder formulation (p < 0.001).
Conclusions and future perspectives: The PK of NFV were ade-
quately described with the developed population model. In future
studies plasma concentrations of the pharmacologically active NFV
metabolite M8 will be added to the model and the influence of
covariates on the PK will be further studied.
Bayesian pharmacokinetically guided dosing of
paclitaxel in patients with non-small cell lung cancer
M. E. De Jonge, H. J. G. D. van Den Bongard, 
A. D. R. Huitema, R. A. A. Mathôt, H. Rosing, 
R. van Maanen, C. Koopman-Kroon, P. Baas, 
N. van Zandwijk, M. Keessen, S. Rodenhuis, 
J. H. Beijnen & J. H. M. Schellens
The Netherlands Cancer Institute and Slotervaart Hospital,
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Aim: Paclitaxel is a taxane derivative with a profound antitumour
activity against a variety of solid tumours. In a previous clinical
study with non-small cell lung cancer patients it was shown that
patients obtaining paclitaxel plasma concentrations of 0.1 mmol/L
during 15 hours or longer showed increased survival1. The purpose
of this study was to evaluate the feasibility of Bayesian dose indi-
vidualisation to attain paclitaxel plasma concentrations above this
threshold concentration during 15 hours or longer.
Methods: Patients with non-small cell lung cancer were treated with
paclitaxel and carboplatin for a maximum of 6 courses every 3
weeks. During the first course, the registered dose (175 mg/m2) of
paclitaxel was administered intravenously (iv) in 3 hours. Carbo-
platin was administered as a 30 min iv infusion in a dose calculated
according to the Calvert formula with a target area under the con-
centration-time curve of 6 mg/ml*min. In subsequent courses, the
paclitaxel dose was individualised based on observed paclitaxel con-
centrations in plasma during the previous course(s). A Bayesian algo-
rithm was used to estimate individual pharmacokinetic parameters,
applying a previously developed population pharmacokinetic model
using the program NONMEM. The paclitaxel dose of a subsequent
course was increased to the lowest dose for which the predicted time
in which the paclitaxel plasma concentration exceeds 0.1 mmol/L was
higher than 15 h (minimum dose 175 mg/m2).
Results: A total of 21 patients have been included in the study (86
evaluable courses). During the first course, the time above the thresh-
old concentration ranged from 7.6 to 31.6 hours; for 9 patients (43%)
the duration of time above the threshold concentration was less than
15 hours (range 7.6–13.4 hours). During subsequent individualized
courses, the time above the threshold concentration was less than 15
hours for 20%, 14%, 23%, 11% and 11% of the patients in the
second, third, fourth, fifth and sixth course, respectively. Dose incre-
ments, ranging from 180 to 240 mg/m2, were performed in 29 of the
65 individualised courses.
Toxicity was reversible and manageable and was mainly haema-
tologic (granulocytopenia grade 3/4 in 81% of the patients).
Conclusion: The results indicate that pharmacokinetically guided
dosing of paclitaxel is feasible and results in a higher percentage of
patients with a duration of time that the paclitaxel concentration of
0.1 mmol/L was achieved during 15 hours or longer compared to stan-
dard dosing of the compound.
1 Huizing MT et al. J Clin Oncol 1997; 15: 317–29.
Cardioversion of atrial fibrillation with a loading dose
of flecainide tablets or an oral solution of a mixture of
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Introduction: An oral loading dose of flecainide could be convenient
both for patients with an episode of atrial fibrillation (AF) admitted
to outpatient departments or for episodic treatment of AF by self
administration outside the hospital.
Objectives: To study the pharmacodynamics and pharmacokinetics of
two oral formulations of flecainide in patients with an episode of AF.
Methods: Patients with AF were randomised, after stratification by
the duration of AF, to receive 3 flecainide tablets of 100 mg or an
oral solution containing 300 mg of flecainide and 20 mg of cisapride.
Blood samples were collected and 12-lead electrocardiograms
(ECG) were obtained at sampling times. The treatment was consid-
ered successful if sinus rhythm (SR) occurred within 5 h. The pro-
portion of patients with SR was calculated by the Kaplan-Meier
method. The treatment groups were compared by using the Log Rank
Test. The maximum flecainide serum concentration (Cmax), the 
corresponding time (Tmax), the absorption rate constant (ka), the
lag-time (tlag) and the area under the curve (AUC) were calcu-
lated. Logistic regression was used to study factors associated with 
cardioversion.
Results: Sixty four patients were randomised. Seven patients con-
verted to SR before ingestion of flecainide and 3 patients were
wrongly included. SR was restored in 17 of 27 patients (63%) in the
oral solution group versus 12 of 27 patients (44%) in the tablets
group (P = 0.14). If AF lasted <24 h 15 of 17 patients (88%) treated
with the oral solution converted to SR, while in 8 of 16 patients
(50%) treated with tablets cardioversion occurred (P = 0.023). Phar-
macokinetic and ECG parameters are shown in Table 1. A duration
of AF <24 h (OR 6.34; 95% CI 1.70–23.73) and a higher ka (OR
1.20 per unit of 0.1 h-1; 95% CI: 1.01–1.44) were associated with
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cardioversion. Other patient characteristics, pharmacokinetic or
ECG parameters did not increase the probability of SR. No serious
arrhythmias were observed.
Conclusions: The probability of cardioversion after oral loading
dosing of flecainide in patients with AF is dependent on ka. Rapid
loading of the effect compartment, i.e. the atria, appears to be criti-
cal to reach cardioversion.
Patient, doctor, and organisational factors affecting
hypertension management in patients with 
type 2 diabetes
P. Denig, C. F. Schaars, W. N. Kasje & 
F. M. Haaijer-Ruskamp
Department of Clinical Pharmacology, University of Groningen,
The Netherlands
Introduction: Tight blood pressure control significantly reduces
morbidity and mortality in diabetic patients, but current hyperten-
sion management seems far from optimal. To develop efficient inter-
vention strategies insight is needed in the specific factors that affect
the quality and outcome of care.
Objective: We aimed to assess the quality of hypertension care in
patients with type 2 diabetes and to identify patient, physician and
organisational factors associated with suboptimal care in general
practice.
Methods: Analysis of process and outcome measures, including
check of blood pressure in the previous year, treatment of hyperten-
sion, and achievement of target blood pressure levels. ACE-
inhibitors were considered as the optimal treatment for patients with
a recorded diagnosis of hypertension or with average blood pressure
levels above 135/85 mm Hg. Data from 895 randomly selected dia-
betic patients were extracted from the computerised medical records
of 95 general practitioners (GPs). A short survey was used to collect
additional physician and organisational characteristics.
Results: For 652 of the 895 patients (73%) one or more blood pres-
sure measurements were recorded in the last year. Of these patients
only 132 (20%) reached a target level of 135/85 mm Hg. In total, 595
patients were classified as having hypertension, 192 of whom
received no treatment (32%), 193 received treatment with an ACE-
inhibitor (32%), and 210 received other antihypertensives. Patients
visiting a special diabetic service, being recently referred to a spe-
cialist, or being overweight had better recordings of their blood pres-
sure. Suboptimal treatment was higher in older patients and smoking
patients. Treatment was better in patients with coronary comorbid-
ity or being recently referred to a specialist. Not achieving the blood
pressure target was related to older age of the patients. Characteris-
tics such as the GP’s working experience, or type and size of the
practice were not associated with the quality of hypertension 
care.
Conclusion: Interventions aimed at improving the quality of hyper-
tension management in diabetic patients should focus more on spe-
cific patients groups than on specific doctors.
Table 1
Pharmacokinetic and ECG parameters
Oral solution Tablets P value
Cmax (mg/l) 0.60 ± 0.17 0.43 ± 0.14 0.0002
Tmax (h) 1.05 ± 0.71 2.37 ± 1.20 <0.0001
ka (h-1) 0.97 ± 0.43 0.48 ± 0.24 <0.0001
tlag (h) 0.30 ± 0.16 0.36 ± 0.19 NS
AUC4h (mg h/l) 1.72 ± 0.52 1.31 ± 0.42 0.003
max QRS (ms) 112 ± 15 112 ± 19 NS
max QTc (ms) 406 ± 18 420 ± 17 NS
Mean values ± SD, QTc interval: during SR in patients without QTc
prolonging drugs.
Determination of alcohol infusion rate by clamping of
breath alcohol concentration – a comparison with
modelled infusion regimens based on individual
pharmacokinetics
G. J. H. Dumont, B. J. Oosterink, S. Paltansing, 
N. van Burgel, M. van Der Linden, R. Schoemaker & 
J. M. A. van Gerven
Centre for Human Drug Research, Leiden
Introduction: Ethanol has profound physiological and psychological
effects, which are usually concentration-dependent. Therefore, EtOH
effects or drug-EtOH interactions are preferably studied at steady
state EtOH-levels. To achieve a steady state EtOH plasma level,
various methods are used, which usually produce adequate average
but variable individual EtOH profiles. A recent algorithm includes
on-line adaptation of EtOH infusion rates based on concomitant
changes in breath alcohol (BrAC).1 This method entails oral loading
followed by intravenous infusion. It has not been widely applied.
Objectives: The clamping method was adapted, using intravenous
EtOH only, and an on-line spreadsheet procedure to guide dosing.
This was compared to a ‘two-step prekinetic procedure’, where
pseudo-steady-state infusion was based on pre-study-day determi-
nation of EtOH kinetics in participants.
Methods: This was an unblinded study in healthy subjects, which
consisted of two parallel designs:
A ‘two-step prekinetic procedure’ started with individually deter-
mined EtOH dispositions during a pre-study occasion. Fifty grams
of EtOH in (10% in glucose 5%) were infused over 1 hour. Breath-
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and serum EtOH levels were measured at 0, 30, 55, 75, 90, 120, 180,
240, 300 and 360 min. Empirical Bayes’ estimates of kinetic para-
meters were then used to simulate individual infusion regimens
aimed to maintain pseudo-steady-state-levels of 0.65 g/L. Regimens
consisted of a constant infusion over 1 hour (loading phase) followed
by a lower constant rate infusion over 3 hours (maintenance phase).
The ‘ethanol clamping procedure’ started with an EtOH loading
phase. After the first six subjects, this was adapted to infusion of 
72 g for 10 min followed by 36 g for 10 min. This loading phase was
followed by a clamping phase, targeted at 0.6 g/L. Using a simple
spreadsheet, the change in BrAC in the previous 10 min measure-
ment interval was plotted dynamically, against the concomitant infu-
sion rate. This produced an increasingly stable trend line with a
regression equation, which was used to determine the infusion speed
for the next 10 min, by plotting the desired BrAC-change (leading
to the target BrAC) in the equation.
Results: The average EtOH profiles for the two procedures are shown
in the graph (left: ‘two-step’, right: ‘clamping’).
Conclusions: Clamping of BrAC results in far more accurate EtOH-
levels than infusion based on PK-modelling.
Teaching resource centre (TRC): teaching clinical
pharmacology in an integrated medical school
curriculum
K. L. Franson1,2, E. A. Dubois1,2, J. M. A. van Gerven1,2, 
F. Cornet1, J. H. Bolk2 & A. F. Cohen1,2
1Centre for Human Drug Research, 2Leiden University Medical
Center
Introduction: Medical professionals are increasingly confronted with
new medicines, rising costs of therapy, and an increasing number of
drug misadventures. It is reasonable to assume that increased knowl-
edge about drugs will increase the quality of drug use. The TRC pro-
vides the LUMC medical students with pharmacological knowledge
based in pathophysiology. Thus, students can see the relevance of a
pharmacological mechanism for a particular disease state.
Methods: We first determined 5 ability outcomes:
Upon completion of the curriculum, students can:
1. explain pharmacological mechanisms of action;
2. explain physiological/pathophysiological mechanisms of disease;
3. critically analyse indications for drugs by comparing pharmaco-
logical and pathophysiological mechanisms;
4. select drug therapy based on pharmacotherapeutic principles;
5. monitor drug therapy based on pharmacotherapeutic principles.
Then provided the students with several learning opportunities for
practicing these outcomes, including using the TRC Pharmacology
computer program and writing the Patient Evaluation and Plan.
TRC Pharmacology computer program (TRCP): Using a newly
developed graphical language for uniformity, a self-study computer
database program was created1. The TRCP program contains graph-
ical material, supportive text and charts, and formative feedback
questions as instruction for outcomes 1 & 2, as the material is pre-
sented in a treeview with links starting with physiology and pro-
ceeding through pathophysiology to pharmacology mechanisms.
Patient Evaluation and Plan (PEP): PEP provides students with a
standardized format for therapeutic decision making and communi-
cating a therapeutic plan (Outcomes 3, 4 & 5). Students are provided
opportunities to practice PEP writing via an online example case that
introduces the PEP process in an interactive step-by-step manner.
Subsequent cases and plans are emailed into a central location for
assessment.
Evaluation: The progress of incorporating the outcomes into the cur-
riculum is being catalogued. The table below shows the percentages
of blocks which adopted the outcomes:
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Outcome 2001–2002 2002–2003
1 51.4 60.7
2 53.3 59.3
3 15 50
4 14 47.1
5 0 52.9
Student evaluations are positive regarding learning strategies and
indicate a preference for higher level assessments and integration.
Next year is expected to yield a higher percentage of pharmacology
outcomes throughout the curriculum.
Conclusions: This process is increasingly being adopted as the
method of providing pharmacology education in the LUMC cur-
riculum. Intial use was limited to the more basic knowledge out-
comes, but now incorporates the application of knowledge.
1 British Journal of Clinical Pharmacology 2001; 52: 623–4.
1 O’Connor, S. et al. Alcohol Clin Exp Res 1998; 22(1):
202–10.
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Trends in antihypertensive drug prescribing in dutch
general practice from 1996 to 2000
J. P. Greving1, P. Denig1, W. J. van Der Veen2, F. W. Beltman2, 
M. C. J. M. Sturkenboom3 & F. M. Haaijer-Ruskamp1
1Clinical Pharmacology, University of Groningen, the
Netherlands, 2General Medicine, University of Groningen, the
Netherlands, 3Medical Informatics, Erasmus MC Rotterdam, the
Netherlands
Introduction: The use of newer antihypertensives, ACE-inhibitors
and A-II-antagonists, has increased considerably in the last decade.
It is unclear to what extent this increase is justified in hypertensive
patients in view of possible comorbidities such as heart failure or
diabetes.
Objectives: To examine trends in the overall and initial treatment of
hypertension, and to assess the relation with comorbidity in general
practice from 1996 to 2000 in the Netherlands.
Methods: We conducted a retrospective cohort study using data from
the Integrated Primary Care Information database. The source pop-
ulation consisted of a dynamic cohort of 27317 persons with a diag-
nosis of hypertension and at least 6 months valid electronic medical
record history. We estimated the point prevalence of overall antihy-
pertensive drug by calendar year by considering as users all persons
with a prescription for an antihypertensive drug in the 6 months prior
to the prevalence date (first Wednesday in October).
As initial treatment we considered the first prescription of an anti-
hypertensive drug within a year after the diagnosis of hypertension.
Separate calculations were made for subpopulations of patients with
a comorbidity of diabetes, heart failure or angina.
Results: From 1996 to 2000, overall antihypertensive drug use
increased from 65% to 71% in all patients with hypertension. In this
population there were increases in the use of diuretics (from 26% to
30%), beta-blockers (from 25% to 30%), A-II-antagonists (from 1%
to 8%), but ACE-inhibitor use remained stable (21%). In hyperten-
sion patients with heart failure ACE-inhibitors were prescribed more
frequently (27%), and also no increase in prescribing was found. In
hypertension patients with diabetes ACE-inhibitor use increased
(from 26% to 32%). Increases in the use of A-II-antagonists did not
differ in the various subpopulations. Regarding initial treatment, the
proportion of patients starting on A-II-antagonists increased (from 4
to 11%), and on ACE-inhibitors remained almost stable (from 23 to
21%). Initial treatment with diuretics or beta-blockers remained just
over 50% during the whole study period.
Conclusion: The use of ACE-inhibitors for hypertension is partly
related to comorbidities for which their use is desirable. The increase
in the use of A-II-antagonists is not confined to specific subpopula-
tions for which their use might be more warranted.
Tacrolimus, but not cyclosporine, dose requirement is
correlated with CYP3A5*3 and CYP3A4*1B genotype
D. A. Hesselink1, R. H. N. van Schaik2, 
P. J. H. Smak Gregoor1, W. Weimar1 & 
T. van Gelder1,3
Departments of 1Internal Medicine, 2Clinical Chemistry and
3Pharmacy, Erasmus MC, Rotterdam, The Netherlands
Introduction: The calcineurin inhibitors (CNI) cyclosporine A (CsA)
and tacrolimus (TRL) are standard immunosuppressive drugs in
many transplantation centers. However, both drugs have a narrow
therapeutic index and show considerable interindividual variation in
their pharmacokinetics (PK). Therefore, therapeutic drug monitoring
is essential to avoid over -or underimmunosuppression. The poor
oral bioavailability of CNI is thought to result from the actions of
the main CNI metabolizing enzymes CYP3A4 and CYP3A5 and the
multi-drug efflux pump, P-gp, encoded by the MDR1 gene. Recently
identified genetic polymorphisms of these 3 enzymes could explain
the observed interindividual variability in CNI PK.
Aim: To determine the role of genetic polymorphisms in CYP3A4,
CYP3A5 and MDR-1 with respect to interindividual variability in
CsA and TRL PK.
Methods: Kidney transplant patients receiving CsA (n = 110) or TRL
(n = 64) were genotyped for CYP3A5*3 and *6 (Kuehl 2001),
CYP3A4*1B (Rebbeck 1998) and MDR-1 C3435T (Hoffmeyer
2000). CsA and TRL concentrations were analysed in whole blood
using the EMIT 2000 assay at 3 and 12 months after transplantation.
Dose-adjusted pre-dose (C0) concentrations were calculated and cor-
related with genotype.
Results: TRL dose-adjusted C0 was significantly higher in CYP3A5
*3/*3 patients (n = 45 or 73%) when compared to *1/*3 plus *1/*1
(wild-type) patients (n = 17 or 27%): Median (range): 94 (34–398)
vs. 61 (37–163) ng/ml per mg/kg; p < 0.0001, Mann-Whitney U test.
CYP3A4*1B allele carriers (n = 10 or 16%) showed a significantly
lower TRL dose-adjusted C0 compared to patients with the wildtype
(*1/*1) genotype (n = 54 or 84%): Median (range): 57 (40–163) vs.
89 (34–398) ng/ml per mg/kg; p < 0.003, Mann Whitney U test. No
evidence was found supporting a role for the MDR-1 C3435T poly-
morphism in TRL PK. For CsA, none of the 3 polymorphisms
studied correlated with dose requirement.
Conclusion: CYP3A5 genotype is strongly correlated with TRL dose
requirement. Patients with the CYP3A5*3/*3 genotype need less
TRL to reach target concentrations compared to CYP3A5*1 allele
carriers and may have a higher likelihood of reaching toxic drug con-
centrations. CYP3A4*1B carriers need more TRL to reach target C0
compared to the CYP3A4*1 carriers and may therefore be at risk of
developing acute rejection.
1 Hoffmeyer S, et al. Proc Natl Acad Sci USA 2000; 97: 3473.
2 Kuehl P, et al. Nat Genet 2001; 27: 383.
3 Rebbeck T, et al. J Natl Cancer Inst 1998; 90: 1225.
Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 11 April 2003
360 57:3 Br J Clin Pharmacol
A Phase I, randomized, open-label, parallel-cohort,
dose-finding study of elacridar (GF 120918) in 
combination with 2.0 mg oral topotecan in cancer
patients
I. E. L. M. Kuppens1, S. Radema2, H. Rosing1, E. Stokvis1, 
M. Swart1, R. C. Jewell3, M. Russo4, A. Karakus2, E. Witteveen2, 
J. H. Beijnen1, E. E. Voest2 & J. H. M. Schellens1
1The Netherlands Cancer Institute, Amsterdam, NL, 2University
Medical Centre, Utrecht, NL, 3&4GSK, RTP, NC and Philadelphia,
PA, USA
Introduction: Increasing oral bioavailability (F) of topotecan, a sub-
strate for the drug efflux proteins BCRP and P-gp, may result in
greater tolerability and may permit prolonged oral administration.
Elacridar is a potent inhibitor of Breast Cancer Resistance Protein
and P-glycoprotein. Inhibition of these proteins significantly
increases F (Kruijtzer et al., 2002).
Objectives: The main goals of this study were to determine the
minimum dose of elacridar required for maximum oral F of topote-
can and to determine the appropriate schedule of co-administration
of oral topotecan and elacridar. Furthermore, safety and tolerability
of this combination and inter-patient variability of the PK of oral
topotecan plus elacridar as compared to iv topotecan alone were
studied.
Methods: twenty patients were randomized to receive 100, 300, 500,
700 or 1000 mg elacridar with 2 mg oral topotecan and to either
simultaneous administration of oral topotecan and elacridar or to
elacridar 60 min prior to oral topotecan, on day 1 or 8 of study.
Patients received iv topotecan on days 15–19 (2.0 mg on day 15, 
1.5 mg/m2 on day 16–19). This was followed by 1.5 mg/m2/d * 5 d,
every 21 d standard treatment. Blood samples were collected on day
1, 8 and 15. Elacridar plasma levels were determined by a HPLC-MS
method. Plasma topotecan lactone and topotecan total (lactone and
carboxylate) levels were determined by a validated HPLC method.
Oral bioavailability of docetaxel in combination with
OC 144-093 (ONT-093)
I. E. L. M. Kuppens1, M. J. van Maanen2, H. Rosing2, 
T. M. Bosch2, A. Fitzpatrick3, J. H. Beijnen1,2
& J. H. M. Schellens1
1The Netherlands Cancer Institute, Amsterdam, NL,
2Slotervaarthospital, Amsterdam, NL, 3Elan Pharmaceutical
Technologies, Ireland
Introduction: Docetaxel has a poor bioavailability (F) when given
orally to man. It is a substrate with high affinity for the MDR1 efflux
protein P-glycoprotein (P-gp). High expression of P-gp combined
with high affinity of docetaxel for the efflux pump is the most plau-
sible explanation for the low systemic availability upon oral admin-
istration. Combination of docetaxel with OC 144-093, a selective
and potent P-gp inhibitor may increase oral F of docetaxel.
Objective: This phase I study was designed to explore the systemic
exposure of docetaxel after combined single oral administration of
docetaxel and OC 144-093 and after a single iv dose of docetaxel
alone. Furthermore the safety of combined treatment was determined
and it was explored whether genetic polymorphisms of the MDR1
gene are associated with variability in docetaxel pharmacokinetics.
Methods: Twelve patients were randomised and received docetaxel
on two occasions. In treatment arm A patients received 500 mg OC
144-093 po followed 30 min later by 100 mg docetaxel po, adminis-
tered in the iv formulation as Taxotere®. This time interval was
altered, after examination of the plasma docetaxel levels of the first
four patients, to intake at the same time.
Two weeks later patients received 100 mg docetaxel iv as a 1 hour
infusion, without OC 144-093. In treatment arm B patients received
the same treatment vice versa. Toxicity was evaluated every course.
MDR1 polymorphisms in exon 12 (C1236T), exon 21 (G2677T) and
exon 26 (C3435T) were determined (by PCR and sequencing).
Plasma concentrations were determined by validated HPLC methods.
PK analysis was performed using WINNONLINTM version 3.0.
Results: Three patients (25%) developed a drug-related SAE. The tox-
icities were all CTC-grade 3 except for neutropenia (grade 4) com-
bined with fever. The two other related SAE’s were diarrhea combined
with rectal blood loss and fever with malaise. Docetaxel 100 mg iv
generates higher Cmax and AUC0–48 values compared to docetaxel po
combined with OC 144-093 (p = 0.001 and p = 0.012). Cmax values are
415 ± 255 (po) and 2126 ± 1010 ng/ml (iv). AUC0–48 values are 844 ±
718 (po) and 2571 ± 1530 ng.h/ml (iv). The ‘apparent F’ was 0.33 ±
0.28 and %CV was 86%. One patient had a homozygous 3435T/T
mutation, which is associated with low intestinal P-gp expression (and
was also homozygous for mutations in exon 21 and 12).
Conclusion: Large intra and interpatient PK variation was found.
Higher plasma levels were observed after iv docetaxel compared
with docetaxel po plus OC 144-093. More patients should be eval-
uated to determine the effect of P-gp single nucleotide polymor-
phism’s on PK values.
Total ‘F’ (= po/iv) Lactone ‘F’ (= po/iv)
0 min 60 min 0 min 60 min
N 13 13 10 11
mean 1.10 1.05 1.08 1.05
SD 0.14 0.13 0.10 0.14
%CV 12 12 9 14
range 0.91–1.34 0.85–1.33 0.93–1.22 0.76–1.28
Results: PK interim analysis has been performed. There was no sig-
nificant effect on the dose of elacridar on the F of oral topotecan over
the studied dose-range of 100–1000 mg. All patients tolerated com-
bination of elacridar and topotecan very well. A total of 15 serious
adverse events have been reported, of which two were considered
drug-related (febrile neutropenia and hemoptysis with thrombocy-
topenia). Both events occurred during cycles of d*5 iv topotecan
therapy.
Conclusion: Administration of 100 mg elacridar and oral topotecan
results in complete apparent bioavailability of oral topotecan. Fur-
thermore co-administration of elacridar and oral topotecan is as
effective as when elacridar is given 60 min prior to topotecan.
Elacridar combined with oral topotecan is well tolerated. In future
studies, a dose of 100 mg elacridar is adequate to optimise oral
bioavailability of oral topotecan.
Kruijtzer, et al. J Clin Oncol 2002; 20(13): 2943–50.
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The effectiveness of HMG-COA reductase inhibitors is
affected by ACE insertion deletion polymorphism
A. H. Maitland-Van Der Zee1,2, B. H. Ch Stricker2, O. H. Klungel1,
J. J. P. Kastelein3, A. Hofman2, J. C. M. Witteman2, 
H. G. M. Leufkens1, C. M. van Duijn2 & A. De Boer1
1Department of Pharmacoepidemiology & Pharmacotherapy,
Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht
University, Utrecht, The Netherlands, 2Department of
Epidemiology & Biostatistics, Erasmus University Medical Centre,
Rotterdam, The Netherlands, 3Department of Vascular
Medicine. Academic Medical Center, Amsterdam, The
Netherlands
Introduction: Inconsistent results have been published on the effects
of pravastatin on angiographically defined coronary atherosclerosis
in subjects with different ACE genotypes.
Aim: To assess whether the effectiveness of statins in the prevention
coronary heart disease and total mortality is influenced by ACE
Insertion (I)/Deletion (D) polymorphism in an elderly population.
Methods: We used data from the Rotterdam study, a prospective pop-
ulation-based cohort study in the Netherlands, which started in 1990
and included 7983 subjects of 55 years and older. Subjects treated
with cholesterol lowering drugs at baseline or a baseline total cho-
lesterol ≥6.5 mmol/l were included. We compared the incidence of
the 4 outcomes total mortality, all coronary heart disease (CHD),
ischemic heart disease (IHD), and all coronary mortality in subjects
who received ≥2 years of statin treatment with the incidence in
untreated subjects by using a Cox proportional hazard model with
cumulative statin use defined as time dependent covariates. Follow-
up was available until 1-1-2000. Analyses were stratified according
to ACE genotypes. All relative risks were adjusted for age, sex, dia-
betes mellitus, systolic blood pressure, bmi, total cholesterol, HDL
cholesterol, history of cardiovascular disease, family history of mi,
current smoking, use of coumarins and platelet inhibiting salicylates.
Results: The adjusted relative risk (RR) mortality from any cause
was 0.65 [95% CI: 0.44–0.95] and of all coronary events 0.81 [95%
CI: 0.55–1.19] for subjects treated with statins for ≥2 years com-
pared with untreated subjects. In subjects with the DD genotype the
RR of developing a coronary event was 1.29 [95% CI 0.62–2.69],
in subjects with the ID genotype the RR was 0.87 [95% CI
0.52–1.45], while in subjects with the II genotype the RR was 0.40
[95% CI 0.15–1.10]. Synergy indices are shown in table 1.
Conclusions: In male subjects with the DD genotype statins did not
reduce the risk of all coronary disease and this lack of effect was sig-
nificantly different from patients with the II genotype in which the
risk reducion of statins was observed. There was no interaction
between statins and ACE genotype on total mortality.
Determinants of persistence with statin use in daily
medical practice
A. K. Mantel-Teeuwisse1, W. G. Goettsch2, 
O. H. Klungel1, A. De Boer1 & R. M. C. Herings2
1Utrecht Institute for Pharmaceutical Sciences (UIPS), Dept. of
Pharmacoepidemiology and Pharmacotherapy, Utrecht
University, Utrecht, The Netherlands, 2PHARMO Institute,
Utrecht, The Netherlands
Background: Persistence with lipid lowering drug use is important
to gain full treatment benefit. Persistence with statins has been
studied in the elderly, but data from the general population is limited.
Aim: To assess persistence with statin use, and to identify factors
affecting persistence in the general population.
Methods: Data were obtained from the PHARMO database includ-
ing linked pharmacy records and hospital discharge records of
865,000 subjects in The Netherlands. In the period 1996–2001, all
new users of statins, defined as patients not receiving any statin for
at least two years before the first dispensing of a statin, were
extracted.
Episodes of statin use were constructed for each patient accord-
ing to Catalan et al., 2000. In case of interruptions between two pre-
scriptions of <45 days, the episode was considered uninterrupted. We
assessed persistence after one and after two years of treatment.
Persons were considered to be persistent if they had a treatment
episode of at least 365 and 730 days, respectively.
Additionally, the association between determinants and failure to
persist (until two years) was assessed using Cox proportional hazard
analysis.
Results: A total of 8335 starters of statins were selected.
Persistence with use at one year was 63.7% (95% confidence inter-
val [CI] 62.7%–64.8%) for all statins, and decreased to 48.5% (95%
CI 47.4%–49.6%) at two years.
Factors predicting failure to persist included older age (Relative
risk [RR] 0.84; 95% CI 0.76–0.93 for those aged 45–64 years com-
pared with those <45 years, and RR = 0.82; 95% CI 0.74–0.91 for
those >65 years compared with those <45 years), a history of anti-
All Male Female
SI* SI* SI*
Total mortality 1.2 (0.4–3.6) 2.6 (0.6–10.9) 0.4 (0.1–2.4)
All CHD 2.7 (0.9–8.6) 7.4 (1.2–46.8) 1.3 (0.3–6.0)
IHD 3.1 (0.7–13.3) NA NA
Coronary mortality 3.2 (0.6–17.7) NA NA
* Adjusted.
NA: not applicable because of low numbers.
Table 1
Synergy indices for DD against II
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hypertensive drug use (RR = 0.91; 95% CI 0.85–0.98), psychotropic
drug use (RR = 1.13; 95% CI 1.06–1.20), or a hospital admission for
ischaemic heart disease in two years previous to the start of statin
treatment (RR = 0.78; 95% CI 0.70–0.88). There was no difference
in persistence according to gender.
Compared to starters with simvastatin, the risk of discontinuation
was lower for atorvastatin (RR = 0.90; 95% CI 0.83–0.96), similar
for pravastatin (RR = 0.99; 95% CI 0.91–1.08), and higher for flu-
vastatin (RR = 1.27; 95% CI 1.12–1.39).
Conclusions: Persistence with statin use declined over time. Factors
affecting persistence included age, previous use of antihypertensive
or psychotropic drugs, a history of ischaemic heart disease and type
of statin.
Catalan VS, et al. Value in Health 2000; 3: 417–26.
Nasal drug delivery to the cerebrospinal fluid:
transport of a hydrophilic drug
P. Merkus, H. J. Guchelaar1, D. A. Bosch2 & 
F. W. H. M. Merkus3
Dept of Otorhinolaryngology, 1Dept of Clinical Pharmacy, 2Dept 
of Neurosurgery, Amsterdam Medical Center, University of
Amsterdam and the, 3Center for Bio-Pharmaceutical Sciences,
University of Leiden, The Netherlands
Aim: The aim of this study was to investigate the possibility of direct
transport of drugs from the olfactory area to the cerebrospinal fluid
(CSF) by intranasal administration (IN) of a hydrophilic drug in
human volunteers. In a large number of animal studies evidence has
been found for drug transport via the nose to the brain [1]. A recent
human study with neuropeptides suggests such a transport [2], but
real proof comparing CSF levels after IN and after intravenous
administration (IV) is missing.
This study evaluates drug CSF levels in patients at the neuro-
surgery department after IN and IV administration of hydroxo-
cobalamin, used in this study as a hydrophilic model compound. It
has been chosen because of safety (vit. B12 analogue) and good nasal
absorption [3].
Methods: We recruited five patients from the Neurosurgery depart-
ment with an external cerebrospinal drain. Each patient received on
the first day hydroxocobalamin IN in a dose of 1500 mg (750 mg in
each nostril) and the second day 75 mg IV. Blood samples and CSF
samples were collected just before and at 5, 10, 20, 30, 40, 60, 120
and 180 minutes after drug administration. Cobalamin levels were
measured with a radioimmunoassay method. Concentration-time
curves of the plasma and CSF levels of cobalamin were compared
after IN and IV administration.
Results and discussion: The mean AUCCSF: AUCplasma ratio of cobal-
amin (0–180 min) after IN and after IV administration were similar
(0.0049), which indicates no additional transport of the drug from
nose to CSF. The uptake of the drug in the CSF follows the same
pattern (see figure) as the uptake in blood after IN and IV with a lag
time of about 30 minutes. It seems plausible that this is the time
needed to pass the blood-brain barrier.
1 Mathison S, et al. J Drug Targ 1998; 5: 415–41.
2 Born J, et al. Nat Neurosci 2002; 5: 514–16.
3 Asselt van DZB, et al. Br J Clin Pharmacol 1998; 45: 83–6.
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When are antimicrobial treatment guidelines not
followed?
P. G. M. Mol1,2, P. Denig1, P. V. Nannan Panday1,2, R. O. B. Gans4,
J. E. Degener3, M. Laseur2 & F. M. Haaijer-Ruskamp1
1Department of Clinical Pharmacology, University Groningen,
2Pharmacy Department, 3Department of Clinical Microbiology,
4Department of Internal Medicine, 2,3,4at University Hospital
Groningen, the Netherlands
Introduction: In an era of increasing bacterial resistance and the
availability of a plethora of antimicrobial agents hospitals develop
policies to promote prudent antimicrobial prescribing. The mainstay
of such policies is often an antimicrobial treatment guideline based
on national and international evidence-based guidelines, on local
resistance patterns and cost-effective drug choices. Adherence to
antimicrobial treatment guidelines is often only moderate. The first
step in improving adherence is the identification of specific problem
areas in order to target the intervention. One may expect that certain
patient characteristics could lead to ‘rational’ non-adherence.
Objective: The aim of this study is to identify relevant patient char-
acteristics and choice of antimicrobial agents to prepare a targeted
intervention.
Methods: Prescribing data were prospectively collected for patients
admitted to the internal medicine department of our hospital from
February 2001–February 2002 with sepsis, urinary tract infections
(UTI), or respiratory tract infections (RTI). Respectively 303, 180
and 595 prescriptions for these indications were issued. The outcome
variable, adherence to the guideline, was assessed by an independent
observer (PVNP) for every prescription taking into account focus of
the infection, aetiology, and co-morbidity as well as culture results
when available. In-vitro test results overruled guideline recommen-
dations if cultured pathogens were insensitive to recommended
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agents. The guideline recommends for empirical treatment of sepsis
and RTI mainly broad-spectrum antibiotics. When in-vitro culture
results become available the guideline recommends narrowing-down
initial broad-spectrum therapy. For UTI, where most cases are
uncomplicated UTI’s, mostly narrow-spectrum antibiotics are 
recommended. The comorbidities included in the analysis were: 
diabetes, alcohol/drug abuse, chronic renal / hepatic failure,
immunosuppressive therapy, COPD, CHF, CVA, urinary catheter of
IV-drains in situ. Disease-severity was indicated by temp >38.5°C,
CRP >100 mg/L-, ASAT >60 U/L-, ALAT >80 U/L-, and creatinine
>130 mg/L, leucocytes >12 or <4 .352 109/L, longer hospital stay
(>11 days) and mortality. Logistic regression was used to analyse the
impact of disease-severity and comorbidity on adherence.
Results: Adherence varied from 37% for UTI, 53% for sepsis to 75%
for RTI. Availability of culture results led to less adherence for RTI
(OR: 0.5 [0.34–0.77]) and more adherence in UTI (OR: 3.24
[1.59–6.63]). No relation was found between disease-severity or co-
morbidity and adherence to the hospital guideline in any of the infec-
tions studied. The most prescribed drug was the broad-spectrum
antibiotic ciprofloxacin for UTI (39%) and sepsis (24%) and co-
amoxiclav for RTI (46%). This drug-choice was mostly not adher-
ent in case of UTI and sepsis, but adherent in case of RTI (adherence
respectively 13%, 29% and 90%). [figure 1]
Conclusion: Doctors seem to choose routinely a broad-spectrum
antibiotic in the three infections included in this study, irrespective
of patient-characteristics. This leads to low adherence in the treat-
ment of infections for which narrow-spectrum antibiotics are rec-
ommended and high adherence when a broad-spectrum antibiotic is
the recommended treatment. These findings indicate that an inter-
vention should target the narrowing of antimicrobial choice and not
specific patient characteristics.
Academic fluoroquinolone prescribing, resistance and
impact of guidelines
P. G. M. Mol1,2, P. V. Nannan Panday1,2, J. E. Degener3, 
T. S. van Der Werf4, F. M. Haaijer-Ruskamp1 & 
R. O. B. Gans4
1Department of Clinical Pharmacology, University Groningen,
2Pharmacy Department, 3Department of Clinical Microbiology,
4Department of Internal Medicine, 2,3,4of University Hospital
Groningen, the Netherlands
Introduction: Excessive ciprofloxacin use has recently been linked
with the emergence of drug-resistant organisms like vancomycin-
resistant enterococci. In our university teaching hospital, we
observed over the past twelve years an increase in ciprofloxacin
prescriptions that was mirrored by an emergence of drug-resistant
enterobacteriacaeae.
Objective: The aim of this study was the effectiveness of guideline-
recommended antimicrobials compared to ciprofloxacin for empiri-
cal treatment of infectious diseases. The guideline recommended
ciprofloxacin only for empirical treatment of urosepsis in the pres-
ence of a catheter (combined with amoxicillin), septic-enteritis or
sepsis with an ulcus as focus (combined with clindamycin), acute
pyelonephritis or prostatis and invasive acute gastro-enteritis and
enterocolitis. Ciprofloxacin had a limited place for culture-targeted
treatment of salmonella species and L. pneumophila for these
indications.
Methods: Prescribing data were collected for 795 patients (1822
antimicrobial prescriptions) admitted to the various sub-departments
of the internal medicine; pulmonology, hematology, kidney-disease,
gastro-enterology, general internal medicine and intensive care from
February 2001–February 2002 with an infectious disease in our
hospital. An independent observer assessed adherence of every
prescription.
Results: Of 144 patients treated with ciprofloxacin only 32% were
treated in accordance with the guideline. The case-mix comprised
mainly patients with sepsis, urinary tract infections (UTI), respira-
tory tract infections (RTI), gastro-enteritis. Empirical therapy with
ciprofloxacin was more adherent than culture-targeted therapy in all
infections included [table 1] Non-adherent treatment was usually too
broad (79 patients). Non-adherent treatment did not cover expected
pathogens (empirical therapy) or cultured pathogens in 14 respec-
tively 5 patients.
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Figure 1.
Adherence of most commonly 
prescribed antimicrobial. Adherent (),
non-adherent ( ).
Table 1
Patients treated with ciprofloxacin (% adherent to
guideline-recommendations)
Culture-
Empirical targeted Total
Sepsis 25 (40%) 15 (20%) 40 (33%)
UTI 29 (14%) 28 (3%) 57 (13%)
RTI 11 (45%) 13 (11%) 24 (50%)
Gastro-enteritis 6 (100%) 3 (67%) 9 (89%)
Other 11 (45%) 3 (33%) 14 (43%)
Total 82 (37%) 62 (26%) 144 (32%)
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The leading principle in treating infectious-diseases is to start
broad and later narrow-down therapy when in-vitro culture results
become available. We reassessed antimicrobial therapy for 41 empir-
ically treated patients where pathogens were cultured from the
appropriate test-material. Guideline-recommended antimicrobial
agents were equally effective (78%) as ciprofloxacin (66%) judged
by in-vitro sensitivity testing of finally cultured pathogens. [table 2]
These guideline recommended agents were frequently less broad-
spectrum agents, e.g. amoxicillin or nitrofurantoin. Even with culture
results available, in five patients therapy with ciprofloxacin was
started that did not cover the cultured pathogens.
Conclusion: Cultured pathogens are well covered by guideline-
recommended antimicrobial agents, therefore no reason exists 
to deviate from guideline-recommendations. In our hospital antimi-
crobial therapy was insufficiently targeted at known resistance pat-
terns of likely or cultured pathogens, clearly leaving room for
improvement.
Reliability of reported ingestion in paracetamol
overdose
J. Mulder1, C. Meulendijks2, C. Neef3, S. Natsch4 & 
C. Kramers1
1Department of Pharmacology/Toxicology, 2MTA and
3Department of Pharmacy, Medisch Spectrum Twente,
Enschede, and 4Clinical Pharmacy, UMC ‘Nijmegen’, P.O. Box
9101, 6500 HB Nijmegen
Introduction: The reported ingestion of patients presenting with a
paracetamol overdose may be unreliable. In the literature ingestion
of less than 150 mg/kg is reported to be safe. If this presumption is
correct, patients reporting a ingestion of less the 150 mg/kg can be
sent home and no paracetamol level has to be measured. At present
it is unknown what patient characteristics predict reliability.
Aim of the study: 1) To compare the reported amount of paracetamol
ingestion to the paracetamol level in the Rumack nomogram, and
determine whether reported ingestion of less than 150 mg/kg predicts
a safe paracetamol level. 2) To identify denominators of unreliabilty
by correlating the calculated reliability with patient characteristics.
Materials and Methods: Based on paracetamol levels measured
between 1990 and 2000 in a university hospital and a large teaching
hospital 260 intoxications were identified. Fourteen cases were lost
for follow up, so 246 intoxications in 197 patients were studied.
Firstly, the reported ingestion was plotted against the blood level. Sec-
ondly, if two levels were available using the computer program
MWPharm the ingested dose was estimated. In this procedure Kel
(elimination rate constant) was calculated using the two available
levels, all other population pharmacokinetic parameters were fixed
and next the ingested dose was estimated ‘by hand’. Next the ‘relia-
bility index’ (= RI) was calculated by deviding the estimated amount
by the reported ingestion. Unreliablity was defined as an RI >2 or <0.5.
RI was correlated with age, gender, co-intake of benzodiazepines
or alcohol, first attempt and psychiatric history. Statistical analysis
was performed using SPSS software. P < 0.05 was considered sig-
nificant.
Results: In 59 intoxications the reported intake was less than 150
mg/kg. In three of them the level was above the treating line of the
nomogram. In 63 intoxications two paracetamol levels were avail-
able. In 20 of them RI was >2 or <0.5. Higher age (>40 years) was
the only factor significantly correlated with unreliability.
Conclusion: 1) Since reported ingestion of <150 mg/kg may result
in a paracetamol level above the treatment line, also in these patients
the level should be assessed. 2) Higher age predicts unreliability.
Table 2
Antimicrobial coverage of in-vitro cultured pathogens (41
patients)
Pathogens covered
Drug choice N patients (% covered) 95% CI
Ciprofloxacin 27 (66%) (49%–80%)
Guideline drugs 32 (78%) (62%–89%)
Amoxicillin pharmacokinetics in (pre)term neonates
S. Reijntjens4, C. Guillaume1, L. Stolk1, 
P. L. J. Degraeuwe2, F. H. M. Nieman3 & A. De Boer4
1Dpts of Clinical Pharmacy, 2Pediatrics and 3Clinical
Epidemiology, 4University Hospital of Maastricht and Dpt of
Pharmacoepidemiology and Pharmacotherapy, Faculty of
Pharmaceutical Sciences, Utrecht, The Netherlands
Introduction: Combination therapy with amoxicillin and gentamicin
is used in our hospital to treat early onset infection of neonates. In
contrast with gentamicin, amoxicillin plasma concentrations are not
measured routinely. Because very few data about plasma concentra-
tions and pharmacokinetics of amoxicillin are available, we have
done a pilot study.
Objectives: Determination of plasma concentrations and pharmaco-
kinetics of amoxicillin and investigation of the correlation of clini-
cal and demographic characteristics with kinetic parameters.
Methods: We have measured amoxicillin concentrations with HPLC
in surplus plasma from routine assays. Data of 24 (pre)term neonates
were analyzed. The amoxicillin dose was 100–200 mg/day in two
doses (n = 23) and three doses (n = 1). Mean (± sd) Gestational Age
(Ga), Post Natal age (PNA) and number of plasma levels were respec-
tively 34.0 (4.9) weeks, 2.2 (1.7) days and 4.5 (1.4) levels/infant.
Because literature indicates, that plasma creatinine (pcr) in the first
weeks of life does not reflect glomerular filtration rate [1], data of
concomitant gentamicin monitoring, 5.4 (1.5) levels/infant, were 
also collected. Pharmacokinetic parameters were calculated with
MW/PHARM 3.50 kinetic software (Mediware, The Netherlands).
Statistical analysis was done with SPSS 11.0 (Chicago, IL, USA).
Results: Dose, top and trough concentrations around second dose and
pharmacokinetic parameters of amoxicillin are shown in the table
below. Because of the wide range in GA, the total population was
split into two subgroups. There was a significant (p < 0.01) differ-
ence for Kel but not for V/W between the two subgroups.
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Discussion and conclusions: For time-dependent antibiotics like
amoxicillin, a T>MIC > 70% or even a continuous target concentra-
tion of 4 ¥ MIC have been proposed. In the light of our measured
amoxicillin concentrations, we suggest to administer the actual daily
dose in three gifts for neonates with GA > 34 weeks. Presently the
number of included neonates is still too small for calculation of 
reliable predictive algorithms with multiple regression analysis.
However the high Pearson’s correlation suggests the possibility 
of dose correction with routinely measured gentamicin elimination
rate.
1 Guignard JP, et al. Pediatrics 1999; 103: e49.
Prevalence and determinants of undertreatment of
hypertension in the Netherlands
H. Schelleman1,2, O. H. Klungel2, W. M. M. Verschuren3, 
A. De Boer2, B. H. Ch. Stricker1 & D. Kromhout4
1Department of Epidemiology & Biostatistics, Erasmus MC,
Rotterdam, Netherlands, 2Department of
Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute
of Pharmaceutical Sciences (UIPS), Utrecht, Netherlands,
3Centre for Prevention and Health Care Research, National
Institute of Public Health and the Environment (RIVM),
Bilthoven, Netherlands, 4Division of Nutrition and Consumer
Safety, National Institute of Public Health and the Environment
(RIVM), Bilthoven, Netherlands
Background: Hypertension is a major risk factor for cardiovascular
diseases. Therefore detection and adequate treatment of hypertension
is important to reduce the incidence of cardiovascular diseases.
Objectives: To assess prevalence and determinants of undertreatment
of hypertension in the general Dutch population.
Methods: We used data from a cross-sectional population based
survey in Amsterdam (A), Maastricht (M), and Doetinchem (D) in
the Netherlands. Between 1996 and 2001 12 762 men and women,
aged 20–79 years, were screened for CVD risk factors. Hyperten-
sion was defined according to the Dutch guidelines of 1997: DBP
95 mm Hg and/or SBP 160 mm Hg, and/or the use of antihyperten-
sive medication for the treatment of hypertension. Among treated
patients uncontrolled hypertension was defined as DBP 90 mm Hg or
SBP 160 mm Hg. Treatment eligibility was, according to recent
guidelines, based on a multifactorial risk profile Multivariate logis-
tic regression was used the assess determinants of undertreatment.
Results: Prevalence of hypertension among men (20–69 years) was
11.0% and for women (20–79 years) 15.6%. A total of 57% of the
hypertensive men and 70% of the hypertensive women were receiv-
ing antihypertensive medication. Of those treated, 44% of the men
and 33% of the women were controlled. Thirty three percent of the
untreated hypertensive men and 41% of the untreated hypertensive
women were eligible for treatment. Among treated hypertensives,
use of cholesterol lowering drugs (OR; 0.41 [95% CI: 0.19–0.87])
was significantly associated with better blood pressure control.
Increasing age (OR; 0.95 [95% CI: 0.92–0.99]), cholesterol med-
ication (OR; 0.26 [95% CI: 0.13–0.53]), and diabetes (OR; 0.15
[95% CI: 0.03–0.70]) were factors associated with a higher proba-
bility of receiving treatment.
Conclusions: More than one third of the untreated hypertensives are
eligible for treatment, whereas more than half of the treated hyper-
tensives have uncontrolled blood pressure. We also identified several
risk factors for undertreatment of hypertension, which allows to
identify and approach groups of patients that need extra attention for
their hypertension treatment.
Kel V/W Top Trough Dose
N (1/h) (l/kg) (mg/l) (mg/l) (mg/kg/d)
GA < 34 14 0.1398 (0.048) 0.580 (0.116) 127 (62) 23 (13) 122 (40)
GA > 34 10 0.246 (0.060) 0.554 (0.130) 7 (5) 7 (5) 117 (34)
Significant Pearson’s correlations were found between Kelamox and GA, pcr, and Kelgenta (p < 0.01) and plasma urea concentration (P < 0.05).
r was respectively 0.639, -0.564, 0.816 and -0.470. No correlation was found between V/W and other covariates.
Thiazide diuretics and the risk of hip fracture
M. W. C. J. Schoofs1,2, M. van Der Klift1,2, A. Hofman1, 
C. E. D. H. De Laet2,3, R. M. C. Herings4, H. A. P. Pols2 & 
B. H. Ch. Stricker1,2,5
1Pharmaco-epidemiology Unit, Department of Epidemiology &
Biostatistics, Erasmus MC, Rotterdam, the Netherlands,
2Department of Internal Medicine, Erasmus MC, Rotterdam, the
Netherlands, 3Department of Public Health, Erasmus MC,
Rotterdam, the Netherlands, 4PHARMO Institute, Utrecht, the
Netherlands, 5Drug Safety Unit, Inspectorate for Health Care,
The Hague, the Netherlands
Introduction: Since the majority of hip fractures are related to osteo-
porosis, treatment of accelerated bone loss can be an important strat-
egy to avoid occurrence of hip fractures. Thiazides have been asso-
ciated with reduced age-related bone loss by decreasing urinary
calcium excretion.
Aims: To examine the association between dose and duration of use
of thiazide diuretics and the risk of hip fracture, and to study the con-
sequences of discontinuation.
Methods: We used data from the Rotterdam Study, a prospective
population-based cohort study in 7983 people aged 55 years and
over. All hip fractures in the study period between June 1, 1991 and
December 31, 1999 were reported by the general practitioners 
and verified by trained research assistants. Information on potential
risk factors was gathered during an interview and clinical examina-
tion at baseline. Details of all dispensed drugs were available on a
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day-to-day basis. To study the association between duration of 
thiazide use and hip fracture, exposure was divided into 7 mutually
exclusive categories: no use, current use for 1–42 days, current use
for 1–365 days, current use for >365 days, last use since 1–60 days,
last use since 61–120 days and last use since >120 days. A Cox pro-
portional hazard model with time-varying exposure was used to
determine the risk of incident hip fracture with thiazide use.
Results: During an average follow-up of 7.4 years, 281 cases of hip
fracture occurred. Relative to non-use, current use of thiazides for
>365 days significantly reduced the risk of hip fracture (hazard ratio:
0.39 [95% CI: 0.18–0.85]). There was no clear dose-dependency.
The protective effect gradually disappeared during a period of 4
months after discontinuation of thiazide use.
Conclusion: This prospective study demonstrates that thiazide
diuretics protect against hip fracture but that this protective effect
disappears within months after discontinuation.
Electro-encephalographic surrogate measures fail to
describe the pharmacodynamic interaction between
ketamine and propofol
M. M. R. F. Struys, H. E. M. Vereecke & E. P. Mortier
Dept. of Anesthesia, Ghent University Hospital, De Pintelaan
185, 9000 Gent, Belgium
Aim of the study: Ketamine potentiates the effects of propofol on
hypnotic signs like ‘unresponsiveness to verbal command’ and ‘loss
of eyelash reflex’ (1). Bispectral index (BIS), an electro-encephalo-
graphic (EEG) derived index, and AAI (A-Line ARX-Index), a mid-
latency auditory evoked potential (MLAEP) derived index, measure
the pharmacodynamic effect of hypnotic drugs (2). As the clinical
signs of the hypnotic state with propofol appear potentiated by ket-
amine, one might expect a reduction in BIS and AAI values. The
present study investigates the accuracy of both BIS and AAI as sur-
rogate measures of the pharmacodynamic interaction between keta-
mine and propofol.
Methods: After IRB approval and written Informed Consent, 15 oth-
erwise healthy patients, scheduled for orthopedic surgery, were
included. BIS and AAI were monitored with frontal electrodes using
BIS-XP EEG (Aspect ®, Newton, Il, USA) and A-Line AEP (Dan-
meter, Odense, Denmark). First, loss of consciousness (LOC) was
induced by infusion of propofol at 100 ml/h until loss of eyelash
reflex and lack of response to verbal command. The calculated
propofol effect-site concentration (Ce prop) at LOC was maintained
by means of a PK/PD driven computerized infusion. A steady state
Ce prop was reached at 4 min after LOC. Then, baseline BIS and
AAI were measured for 1 minute. Five minutes after LOC a bolus
ketamine (0.4 mg) was administered followed by an infusion of 
1 mg/kg/h for 17 minutes. Baseline BIS and AAI were compared
with all the minute by minute data, using a paired T-test with Bon-
ferroni correction. Coefficient of variation (CV = standard devia-
tion/mean) was calculated.
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Results: Patients were 40 ± 16 years, 172 ± 8 cm, 67 ± 16 kg. Fig. 1
shows BIS and AAI changes from baseline (B) with ketamine. BIS
increased (p < 0.003) from minute 3 to 8 after ketamine bolus
without increase in CV. AAI didn’t change with ketamine, but vari-
ability (described as CV) increased.
Conclusions: The expected decrease in BIS and AAI was not
observed when combining propofol and ketamine. This makes them
inadequate for measuring pharmacodynamic interaction. BIS
changes can be explained by dominant frontal rhythmic theta activ-
ity with increased amplitude and AAI changes by a fluctuation in the
primary sensory cortex or at a lower level.
1 Acta Anaesth Sc 1999; 43: 212.
2 Anesthesiology 2002; 96: 803.
Bioavailability of ibuprofen from hot-melt extruded
mini-matrices
W. M. van Den Abeele1, C. De Brabander2, 
C. Vervaet2, J. P. Remon2 & L. M. van Bortel1
1Heymans Institute of Pharmacology, Ghent University, De
Pintelaan 185, 9000 Gent, Belgium; 2Laboratory of
Pharmaceutical Technology, Ghent University, Harelbekestraat
72, 9000 Gent, Belgium
Ibuprofen is a non-steroidal anti-inflammatory drug with a short half-
life of approximately 2 hours. As a consequence, multiple daily
dosing is required. Use of sustained release dosage forms can resolve
this problem, enhancing patient compliance. The present study
investigates the in-vivo performance of two novel mini-matrix for-
mulations with sustained release properties in healthy volunteers,
compared with a commercially available sustained release formula-
tion as reference.
Methods: Each drug formulations contained 300 mg ibuprofen. The
formulations tested were:
Data are presented as mean ± SD
Ibu-slow® F-1 F-2
Tmax (h) 2.7 ± 0.8 4.1 ± 0.9 6.4 ± 3.8
Cmax (mg/ml) 14.1 ± 3.4 7.8 ± 2.7a 6.1 ± 1.1a
AUC0–24 h (mg.h/ml) 104.1 ± 34.0 79.0 ± 24.5a 80.9 ± 24.1a
HVDt50%Cmax (h) 5.2 ± 2.0 7.6 ± 3.3 12.0 ± 6.3a
ap < 0.05 difference from Ibu-slow® according to a two-way
ANOVA.
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F-1: 30% ibuprofen, 35% ethylcellulose and 35% hydroxypropy-
lmethylcellulose (Metolose® 60 SH 50),
F-2: 60% ibuprofen, 20% ethylcellulose and 20% xanthan gum
F-3: Ibu-slow® 600 mg (Therabel Brussels, Belgium, half a
tablet).
Oral bioavailability was studied in a 3-period double blind ran-
domised cross-over study. Nine apparently healthy subjects (3 males,
6 females) entered the study. They were from 18 to 55 years old,
their weight and body mass index were within normal range. For-
mulations were given in fasting conditions. Washout between drug
administrations was at least 6 days. Ibuprofen was assayed by
HPLC-UV detection. Statistical analysis was done using a two-way
analysis of variance (ANOVA) and Scheffe test.
Results: Of oral bioavailability are shown in Table 1.
HVDt50%Cmax: time period with plasma concentrations above 50% of
Cmax.
Conclusions: The present study shows that the mini-matrix formu-
lated with hydroxypropylmethylcellulose (F1) and the mini-matrix
formulated with ethylcellulose in combination with xanthan gum
(F2) can be used as sustained release formulations. Especially the
sustained release effect of the formulation with xanthan was statis-
tically larger than the effect of the commercially available Ibu-
slow®, as evidenced by the longer HVDt50%Cmax.
Human adenosine kinetics measured by microdialysis
E. E. M. van Ginneken, Md1, P. van Den Broek2, 
P. Smits, Md, Phd1,2 & G. A. Rongen, Md, Phd1,2
1Department of General Internal Medicine and 2Department of
Pharmacology-Toxicology, University Medical Centre Nijmegen,
Nijmegen, The Netherlands
Background: Costa et al. (2000) described the microdialysis method
as a promising tool to study human adenosine (ADO) kinetics at rest
as well as during exercise. In protocol 1, we aimed to explore the
contribution of catheter related tissue injury in exercise-induced
ADO release. Protocol 2 explored whether the microdialysis tech-
nique is able to detect a gradient between circulating and interstitial
ADO (as reported from in vitro studies), and to study the influence
of the nucleoside transport inhibitor dipyridamole on the gradient
between circulating and interstitial ADO.
Methods: Protocol 1: A microdialysis catheter was inserted into the
flexor digitorum superficialis muscle. HPLC-measurement of intra-
muscular (IM) ADO, creatine (C) and creatine phosphate (CP) were
performed during 2 bouts of intermittent handgrip, one hour apart,
at 50% Fmax, for 15 minutes, every 5 seconds (n = 6 healthy vol-
unteers). C and CP were measured as markers of myocytic cell
damage (n = 4). Protocol 2: a second microdialysis catheter was
inserted retrogradely into a deep cubital vene and the ipsilateral
brachial artery was cannulated. Simultaneous measurements of IM
and intravenous (IV) forearm ADO were performed during intra-
brachial infusion of increasing ADO doses with/without dipyri-
damole (n = 10, see figure 1 for doses). Forearm blood flow (FBF)
was measured by venous occlusion plethysmography.
Results: Protocol 1: 2 bouts of handgrip induced a rise in dialysate-
ADO of 0.4 ± 0.2 vs 0.2 ± 0.1 nmol/ml (t-test n = 6, p > 0.1), and a
rise in (C + CP) from 165 ± 7 vs 36 ± 22 nmol/ml (Wilcoxon, n =
4, p > 0.1). Protocol 2: Fig. 1 shows dialysate ADO concentrations
during intra-arterial infusion of respectively saline, ADO 20, 60 and
200 nmol/min/dl of forearm volume, dipyridamole 200 nmol/dl/min
and dipyridamole simultaneously with the lowest ADO dose:
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During infusion of the lowest ADO dose with and without dipy-
ridamole resp. FBF mounted 6.9 ± 1 vs 31.9 ± 3.9 (n = 10, p < 0.05),
IM dialysate ADO concentrations were 0.08 ± 0.02 vs 0.06 ± 0.01
(n = 10, p = NS), and IV ADO concentrations were 0.07 ± 0.02 vs
0.2 ± 0.06 (p = 0.046).
Conclusions: The exercise-induced increase in interstitial adenosine
is largely caused by catheter and exercise-related cell injury. Nucle-
oside transport prevents systemic spill of Adenosine during intra-
arterial infusion. The microdialysis technique is able to detect the
considerable gradient between intra-muscular and intravascular
adenosine which is not relevantly reduced by dipyridamole.
Correlation between riluzole clearance and CYP1A2
activity in patients with amyotrophic lateral sclerosis
H. J. M. van Kan1, G. J. Groeneveld2, 
J. Sastre Toranˇo1, M. Spieksma1, L. H. van Den Berg2 & 
H. J. Guchelaar1
1Academic Medical Center, Dept. of Clinical Pharmacy, P.O. Box
22660, 1100 DD Amsterdam, Netherlands, 2University Medical
Center Utrecht, Neuromuscular Center
Aims: Riluzole (Rilutek®) is the only drug licensed for the treatment
of amyotrophic lateral sclerosis (ALS) and is prescribed in a fixed
dosing schedule of 50 mg twice daily. Its pharmacokinetics (PK) in
ALS patients is leading to variable serum drug concentrations.1 Rilu-
zole is assumed to be mainly metabolized by cytochrome P450
enzyme subtype 1A2 (CYP1A2). Variability in the enzyme activity
may explain the drugs PK. A strong correlation of its clearance with
CYP1A2 activity was expected. Results of this study may be useful
to improve therapeutic outcome and to minimalize side effects.
Methods: Data were collected from 30 ALS patients from the outpa-
tient clinic as part of a study protocol after approval by the hospital
medical ethics committee. To estimate CYP1A2 activity the parax-
anthine/caffeine molar serum concentration ratio was measured 6
hours after the administration of a 200 mg oral caffeine dose.2 Indi-
vidual riluzole clearance was estimated using peak and trough serum
concentration measurements during steady state therapy with riluzole
50 mg bid and a Bayesian iterative procedure (1-compartment open
model).3,4 Riluzole, caffeine and paraxanthine serum concentrations
were measured using validated liquid chromatographic assays.
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Results: Between the P/C ratio and riluzole clearance we found a
positive correlation (r = 0.594; p = 0.0005). See figure 1.
Discussion: Based on the correlation found in this study measure-
ment of CYP1A2 activity offers a relatively simple method to
roughly estimate the riluzole clearance in ALS patients. This may
facilitate therapeutic drug monitoring and individualization of treat-
ment. However, the correlation shows substantial residual variation
that may be caused by other unknown factors. Also, a concentration-
effect relationship has not been established.
Conclusions: This study shows a linear correlation between CYP
1A2 activity and riluzole clearance in patients with ALS.
1 J Neurol Sci 2001; 191(1–2): 121–5.
2 Biomed Chrom 1999; 13: 309–14.
3 Clin Pharmacol Ther 1997; 62(5): 518–26.
4 Lancet 1996; 348(9030): 795–9.
Calcitonin gene-related peptide-induced vasodilation in
the human forearm: inhibition by the CGRP-receptor
antagonist CGRP8–37
F. H. M. Vanmolkot & J. N. J. M. De Hoon
Center for Clinical Pharmacology, University Hospital
Gasthuisberg (K.U. Leuven), Leuven, Belgium
Calcitonin-gene related peptide (CGRP) is a potent endogenous
vasodilator, for which at least two CGRP-receptor subtypes (CGRP1
and CGRP2) have been proposed. The C-terminal fragment of CGRP,
CGRP8–37, is considered a moderately selective antagonist for the
CGRP1 receptor. In vitro and animal studies have shown that CGRP-
induced vasodilation is inhibited by CGRP8–37. However, human in
vivo data confirming these results are still lacking.
The objectives of this study were to investigate the effects of
CGRP8–37 on resting forearm blood flow (FBF) and on CGRP-
induced vasodilation in vivo in humans.
Bilateral venous occlusion plethysmography was used to assess
FBF response to increasing infusion rates of CGRP (1, 3 and
10 ng.min-1.dL-1 forearm) into the brachial artery of 12 healthy sub-
jects. Dose-response curves were constructed during co-infusion of
CGRP and placebo (NaCl 0.9%). After washout (90 min), CGRP
infusions were repeated during simultaneous infusion with placebo
(time-control experiments, n = 6) and CGRP8–37 (333 ng.min-1.dL-1
forearm, n = 6). FBF-ratio was calculated (FBF-ratio = FBF
infused/FBF non-infused arm). Dose-response curves were com-
pared using repeated measures ANOVA and Wilcoxon’s matched-
pairs signed-rank test. Data are presented as mean ± SEM.
FBF in the non-infused arm, blood pressure and heart rate did not
change during the experiments. CGRP increased FBF from 3.2 ± 0.3
at baseline to 4.8 ± 0.3, 7.7 ± 0.7 and 12.7 ± 1.0 mL.min-1.dL-1
forearm, respectively (P < 0.001, n = 12). FBF-ratio during the first
co-infusion of CGRP and placebo (1.9 ± 0.2, 3.1 ± 0.3 and 5.2 ± 0.8)
did not differ from FBF-ratio during the second co-infusion of CGRP
and placebo (2.1 ± 0.1, 3.0 ± 0.1 and 4.7 ± 0.3). Baseline FBF was
not affected by infusion of CGRP8–37 (3.1 ± 0.3 versus 3.1 ± 0.3
mL.min-1.dL-1 forearm). CGRP8–37 attenuated the CGRP-induced
increase in FBF-ratio (2.2 ± 0.3, 3.3 ± 0.2 and 5.7 ± 0.4 during infu-
sion with placebo versus 1.6 ± 0.1, 2.0 ± 0.3 and 3.5 ± 0.6 during
infusion with CGRP8–37, P = 0.012).
Intra-brachial infusion of CGRP results in a dose-dependent and
repeatable forearm vasodilator response. In the human forearm,
CGRP8–37 has no effect on resting blood flow, but effectively inhibits
CGRP-induced vasodilation, suggesting involvement of the CGRP1
receptor.
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Figure 1
P/C ratio vs. riluzole clearance (n = 30)
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The risk of overanticoagulation in patients with
cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on
acenocoumarol or phenprocoumon
L. E. Visser1,2, M. van Vliet3, R. H. N. van Schaik3, 
A. A. H. Kasbergen4, P. A. G. M. De Smet5,6, A. G. Vulto2, 
A. Hofman1, C. M. Van Duijn1 & B. H. Ch. Stricker1,7
1Pharmacoepidemiology Unit, Departments of Internal Medicine
and Epidemiology & Biostatistics, Erasmus MC, Rotterdam, the
Netherlands, 2Hospital Pharmacy, Erasmus MC, Rotterdam, the
Netherlands, 3Department of Clinical Chemistry, Erasmus MC,
Rotterdam, the Netherlands, 4Stichting Trombosedienst & 
Artsenlaboratorium Rijnmond, Rotterdam, the Netherlands, 
5Scientific Institute Dutch Pharmacists, The Hague, the 
Netherlands, 6Department of Clinical Pharmacy, University
Medical Centre St Radboud, Nijmegen, the Netherlands, 7Drug
Safety Unit, Inspectorate for Health Care, The Hague, the
Netherlands
Introduction: Cytochrome P4502C9 (CYP2C9) is the main enzyme
implicated in coumarin metabolism. The variant alleles CYP2C9*2
and CYP2C9*3 are associated with increased sensitivity to warfarin
(Aithal et al., 1999; Taube et al., 2000; Higashi et al., 2002; Scordo
et al., 2002). An effect on acenocoumarol dose requirements,
however, seems to be absent or not clinically relevant (Thijssen et al.,
2000; Hermida et al., 2002; Tassies et al., 2002) and the consequences
for the metabolism of phenprocoumon has not yet been established.
Aim: We investigated CYP2C9 polymorphisms in relation to stabil-
ity of the anticoagulant level during the first six weeks of treatment
and its effect on the maintenance dose in a cohort of 1124 patients
treated with acenocoumarol or phenprocoumon.
Methods: Independent-samples t tests were used for comparing the
mean number of INR assessments and the mean INR during the first
six weeks of treatment and the differences in mean maintenance dose
during the rest of the follow-up between carriers of variant alleles
and the wild type genotype. Relative risks (RR) with 95% confidence
intervals (CI) were calculated for comparing the proportion of
patients with an INR ≥ 6.0 between variant and wild type genotypes.
A multivariate linear regression model was used to assess the effect
of allelic variants on the coumarin maintenance dose, while control-
ling for differences in cofactors.
Results: After a standard starting dose of acenocoumarol, there was
a statistically significant difference in the first INR between patients
with the variant genotypes and those with the wild type. Almost all
acenocoumarol-treated patients with a variant genotype had a sig-
nificantly higher mean INR and had a higher risk of an INR ≥ 6.0
during the first six weeks of treatment. A clear genetype-dose rela-
tionship was found for acenocoumarol-treated patients. For patients
on phenprocoumon no significant differences were found between
variant genotypes and the wild type genotype.
Conclusion: Individuals heterozygous for either CYP2C9*2 or
CYP2C9*3, as well as those with two variant CYP2C9 alleles
require a significantly lower dose of acenocoumarol than wild type
patients. Phenprocoumon seems to be a clinically useful alternative
in patients carrying the CYP2C9*2 and *3 alleles.
1 Aithal GP, et al. Lancet 1999; 353: 717–19.
2 Hermida J, et al. Blood 2002; 99: 4237–9.
3 Higashi MK, et al. JAMA 2002; 287: 1690–8.
4 Scordo MG, et al. Clin Pharmacol Ther 2002; 72: 702–10.
5 Tassies D, et al. Haematologica 2002; 87: 1185–91.
6 Taube J, et al. Blood 2000; 96: 1816–19.
7 Thijssen HH, et al. Pharmacogenetics 2000; 10: 757–60.
Determinants of elevations of lithium serum levels into
the toxic range
I. Wilting1,2, M. Moolenaar1, K. L. L. Movig1, Y. A. Hekster3, 
J. R. B. J. Brouwers4 & A. C. G. Egberts1,2
1Hospital Pharmacy Midden-Brabant, TweeSteden Hospital and
St. Elisabeth Hospital, Tilburg, Netherlands, 2Department of
Pharmacoepidemiology and Therapeutics, Utrecht Institute for
Pharmaceutical Sciences, Utrecht, Netherlands, 3Department of
Clinical Pharmacy, University Medical Centre Nijmegen,
Nijmegen, Netherlands and 4Hospital Pharmacy, General
Hospital Tjongerschans, Heerenveen, Netherlands
Background: Lithium salts are the major treatment option in patients
with bipolar disorder. An important limitation of the therapeutic use
of lithium is, the narrow therapeutic window [0.6–1.2 mmol/L];
small increases in lithium serum level can result in toxic concentra-
tions and related serious adverse reactions. Concomitant medication
(co-medication) is a highly suspected cause of toxic lithium serum
levels (Harvey et al., 1994). However, the impact of such drug-drug
interactions in daily clinical practice is unknown.
Objectives: To determine the impact of co-medication on the eleva-
tion of lithium serum levels into the toxic range; ≥1.3 mmol/L.
Methods: A retrospective case-control study was conducted among
Dutch patients on lithium treatment. Cases were patients ≥18 years of
age having a regularly measured lithium serum level of 
≥1.3 mmol/L and an increase of at least 50% relative to the previous
measurement. Suspected intentional intoxications were excluded. Con-
trols were randomly selected from patients having a lithium serum level
within the therapeutic window on the index date, that differed less than
50% from the previous measurement. Both cases and controls had at
least two lithium serum levels within the therapeutic window prior to
inclusion and had been on lithium treatment for at least three months.
Patient serum concentrations were collected for: creatinin, TSH, potas-
sium and sodium. From the patients medical record information on type
of physician, lithium doses (on the index and the pre-index date) and
selected co-medication (use of NSAIDs, diuretics, RAS inhibitors,
thyreomimetics, corticosteroids and antibiotics) was gathered. Starters
on selected co-medication were identified. Starting was defined as a
first prescription within 30 days before the index date and no pre-
scription for that medication in the 120 days before.
Results: Forty-seven cases and an equal number of controls were
included. Twenty-one cases and ten controls used co-medication (OR
3.0 [CI: 1.2–7.4]). Four cases and no controls were starters, OR 9.8
[CI: 0.5–187.9]. Cases were more frequently women (74%) than
controls (60%), OR 2.0 [CI: 0.8–4.8]. No association was found with
age, type of physician or change in lithium doses and toxic lithium
serum levels.
Conclusions: From these results we conclude that (starting of) co-
medication is a determinant for elevations of lithium serum levels
into the toxic range, in daily clinical practice. Further research is nec-
essary to elucidate what (classes of) drugs are most important and
in which patients such drug-drug interactions occur.
Harvey et al., Drugs Safety 1994; 10(6): 455–63.

